Health Care·Biotechnology·$24.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.60 | N/A | +28.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.60 | N/A | +28.00% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management is pleased with the earnings results, particularly the EPS beat. They emphasized their commitment to innovation and growth.
Management expressed satisfaction with the EPS performance.
They highlighted ongoing efforts in product development.
Future growth potential remains a focus for the company.
United Therapeutics reported a strong EPS performance, exceeding expectations by 28%. The stock reacted positively, gaining 0.94%. The lack of revenue figures and guidance leaves some uncertainty, but the management's focus on growth and product development may reassure investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
FIRSTENERGY CORP
Feb 25, 2013